Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes

Tissue Antigens

Volumn 48, Issue 1, 1996, Pages 22-31

  Bernhard, H ^a   Jager E ^b   Maeurer, M J ^c   Meyer Zum Buschenfelde K H ^a   Knuth, A ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b KRANKENHAUS NORDWEST   (Germany)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cytotoxic T lymphocyte; HLA; Melanoma; Peptide; Renal cell carcinoma; Restriction

Indexed keywords

CD8 ANTIGEN; HLA A2 ANTIGEN; HLA B8 ANTIGEN; TUMOR ANTIGEN;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA CELL; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR CELL LINE;

EID: 0029820314     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1996.tb02601.x     Document Type: Article

References (35)

1. Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer 1978: 42: 2282-92.
2. De Kernion J, Rammig K, Smith R. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978: 120: 148-52.
3. Finke JH, Tubbs R, Conelly B, Pontes E, Montie J. Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann N Y Acad Sci 1987: 532: 387-94.
4. Cohen PJ, Lotze MT, Roberts JR, Rosenberg SA, Jaffe ES. The irnmunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol 1987: 129: 208-16.
5. Störkel S, Keymer R, Steinbach F, Thoenes W. Reaction patterns of tumor infiltrating lymphocytes in different renal cell carcinomas and oncocytomas. EORTC-Genitourinary Group Monograph 1992: 11: 217-23.
6. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin 2 or high-dose interleukin 2 alone. N Engl J Med 1987: 316: 889-97.
7. Aulitzky W, Gastl G. Aulitzky WE et al. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 1989: 7: 1875-84.
8. Rubin TT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res 1989: 49: 7089-92.
9. Belldegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization and antitumor activity. Cancer Res 1988: 48: 201-14.
10. Knuth A, Wölfel T, Klehmann E, Boon T, Meyer zum Büschenfelde KH. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Pmc Natl Acad Sci USA 1989: 86: 2804-8.
11. Finke JH, Rayman P. Edinger M et al. Characterization of a human renal cell carcinoma specific cytotoxic CDS+ T cell line. J Immunother 1992: 11: 1-11.
12. Schendel DJ, Gansbacher B, Oberneder R et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. J Immunol 1993: 151: 4209-20.
13. Van der Eynde B, Hainaut P, Herin M et al. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer 1989: 44: 634-40.
14. Van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991: 254: 1643-7.
15. Wölfel T, Hauer M, Klehmann E et al. Distinct shared antigens in human melanoma recognized in association with HLA-A2 and defined by cytotoxic T lymphocyte (CTL) clones. Int J Cancer 1993: 55: 237-44.
16. + tumor-infiltrating lymphocytes. J Immunol 1994: 1202-15.
17. Anichini A, Maccalli C, Motarini R et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993: 177: 989-98.
18. Brichard V, van Pel A, Wölfel T et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993: 178: 489-95.
19. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994: 180: 1-4.
20. Coulie PG, Brichard V, van Pel A et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994: 180: 35-42.
21. Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994: 91: 3515-19.
22. Storkus WJ, Zeh HJZ, Maeurer MJ, Salter RD, Lotze MT. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 1993: 151: 3719-27.
23. Wölfel T, Schneider J, Meyer zum Büschenfelde K-H, Rammensee H-G, Rötzschke O, Falk K. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1. Int J Cancer 1994: 57: 413-18.
24. Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994: 264: 716-19.
25. Slingluff Jr CL, Cox AL, Stover Jr JM, Moore MM, Hunt DF, Engelhard VH. Cytotoxic T-Lymphocyte response to autologous human squamous cell cancer of the lung: epitopes reconstitution with peptides extracted from HLA-Aw68. Cancer Res 1994: 54: 2731-7.
26. Castelli C, Storkus WJ, Maeurer MJ et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995: 181: 363-8.
27. Carrel S, Johnson PJ. Immunologic recognition of malignant melanoma by autologous T lymphocytes. Curr Opin Oncol 1993: 5: 383-9.
28. Wölfel T, Klehmann E, Müller C, Schütt KH, Meyer zum Büschenfelde KH, Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989: 170: 297-810.
29. Brouwenstijn N, Gaugler B, Krüise KM, van der Eynde B, Schrier PI, Boon T. Isolation of renal cell carcinoma-specific cytotoxic cells. Third International Symposium on the Biology of Renal Cell Carcinoma. 1994.
30. Bernhard H, Karbach J, Wölfel T et al. Cellular immune response to human renal cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T lymphocytes (CTL) clones, Int J Cancer 1994: 59: 1-6.
31. Herin M, Lemoine C, Weynants P et al. Production of stable cytolytic T cell clones directed against autologous human melanoma, Int J Cancer 1987: 39: 390-6.
32. Mc Michael AJ, Parham P, Rust N, Brodsky FM. A monoclonal antibody that recognizes an antigenic determinant shared by HLA-A2 and B17. Hum Immunol 1980: 1: 121-9.
33. Bodmer H, Ogg G, Gotch F, Mc Michael A. Anti-HLA-A2 antibody-enhancement of peptide association with HLA-A2 as detected by cytotoxic T lymphocytes. Nature 1989: 342: 443-6.
34. Thoenes W, Störkel S, Rumpelt HJ, Moll R. Cytomorphical typing of renal cell carcinoma - a new approach. Eur Urol 1990: 18: 6-9.
35. Bakker AB, Schreurs MW, de Boer AJ et al. Melanocyte lineage-specific antigen gpl00 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994: 179: 1005-9.